Modern medicine: Azithromycin tablets and Diprophylline injections passing generic drug consistency evaluation.

Yaoxian Notice: Modern Pharmaceuticals announced that the company and its wholly-owned subsidiary, China Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., have received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. Azithromycin tablets and aminophylline injection have passed the generic drug quality and efficacy consistency evaluation. Azithromycin tablets are used to treat infections caused by sensitive bacteria, with a sales revenue of 685 million yuan in national public medical institutions and urban pharmacies in 2024. Aminophylline injection is used to treat bronchial asthma, with sales revenue of 135 million yuan in national public medical institutions in 2024. This consistency evaluation is beneficial for product market expansion and sales.